SWINDON, UNITED KINGDOM

Our Swindon facility houses our Zydis® fast dissolving tablet development and manufacturing operation as well as a CMC pharmaceutical analytical lab services unit that offers ASAP stability.

Size: 253,314 ft²

SWINDON 360° VIRTUAL TOUR

ACCESSIBILITY STATEMENT

Click this link to see an Accessibility statement for the Swindon Site.

CAPABILITIES:

• Development and clinical technologies:
  • Regulatory consulting services
• Microbiology
• QP Release
• Raw material and finished product release testing
• Stability testing and storage
• Oral Dispersable Tablets
• Stability Testing

FEATURED TECHNOLOGIES:

• Zydis® Fast-Dissolve Technology

ACCREDITATIONS

• ANVISA Approved
• CT-PAT approval for Catalent US
• EMA Approved
• FDA Approved
• Approved by Turkey’s MOH (Ministry of Health)

SALES INQUIRIES

Reach out to one of our experts to discuss any of our offerings or a specific solution for your project challenges.

CAREERS

We recognize talent is our most important asset. To explore a career with Catalent, visit our Careers Section to submit your resume.

GENDER PAY GAP REPORT

Catalent UK Swindon Zydis Limited (“Catalent Zydis”) continues to be an organisation committed to the growth, development, and engagement of our people, within an inclusive culture.  As a UK based organisation of over over 250 employees, we now report our gender pay data. Please download here.

CATALENT UK RETIREMENT AND DEATH BENEFIT PLAN (“PLAN”) – CHAIR’S STATEMENT RELATING TO THE DEFINED CONTRIBUTION SECTION

The defined contribution section of the Plan (DC Section) is now closed and all members’ benefits in the DC Section have been transferred out of the Plan.

Before the DC Section closed, the chair of trustees was required to publish a statement that covered the Statement of Investment Principles (SIP) in relation to the default arrangement and the charges and transaction costs borne by members. The most recent and final chair’s statement was prepared in December 2018 and can be accessed here. Please note that this is a historic document which was prepared before the DC Section closed and is provided for information only. The file can be accessed here.

CATALENT UK RETIREMENT AND DEATH BENEFIT PLAN (“THE PLAN”) DB SECTION STATEMENT OF INVESTMENT PRINCIPLES (“SIP”)

This Statement sets out the Principles governing decisions about the investments of the Plan. The Principles outlined in this Statement of Investment Principles became effective following the delegation of certain decision making powers by the Trustees to Hewitt Risk Management Services Limited (the “Fiduciary Manager”).

The file can be accessed here.

CATALENT UK RETIREMENT AND DEATH BENEFIT PLAN (“THE PLAN”) DB SECTION ENGAGEMENT POLICY IMPLEMENTATION STATEMENT (“EPIS”)

New regulations that apply from 1 October 2020 have set out requirements for the trustees of defined benefit pension schemes regarding the production of an Engagement Policy Implementation Statement (“EPIS”). The attached EPIS sets out information on how the trustees have put the statement of investment principles (“SIP”) into practice, particularly in relation to stewardship and engagement.

The file can be accessed here.

CATALENT UK TAX STRATEGY

The purpose of this statement is to satisfy the UK legislative requirements of Schedule 19 Finance Act 2016 in relation to the publication of tax strategy insofar as it affects the UK companies in the Catalent group for the year ended 30 June 2024. Please download here.